By: Nadeemy Haded
British pharmaceutical company GlaxoSmithKline PLC has begun collaborating with the Alliance for Pandemic Preparedness Innovations to contribute to efforts to develop a vaccine against the Coronavirus virus outbreak.
A statement issued by both GlaxoSmithKline and the Alliance, a private entity based in Norway, said on Monday that they are cooperating to develop an anti-virus vaccine, which recently spread in China.
The statement said that GlaxoSmithKline will provide "a platform technology to enhance the effectiveness of medical treatment" to develop an anti-Coronavirus vaccine, also known as "Corona Wuhan" as well as "2019 - NCOV", adding that the British company will cooperate with entities Funded by the Alliance for Epidemic Preparedness Innovations.
Using the platform to enhance the effectiveness of medical treatment will allow more doses of the vaccine to be produced, and thus increase its availability to more people, according to Reuters.
It is noteworthy that the rapidly spreading virus has, so far, killed more than 362 people in China, spread to more than 24 countries and caused the world's second largest economy to be affected by travel stops and companies closed.
To date, there is no known vaccine to treat the Coronavirus, although more than 486 people have recovered from the disease.
Many organizations, including the "Alliance for Epidemic Preparedness Innovations," are working to develop a drug for the virus, which first circulated in Wuhan, Hubei Province, China in late December.